STOCK TITAN

Vertex Pharmaceuticals (VRTX) Stock News, Jan-Apr 2024

VRTX NASDAQ

Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.

Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags

FAQ

What is the current stock price of Vertex Pharmaceuticals (VRTX)?

Vertex Pharmaceuticals (VRTX) last closed at $536.45.

What is the market cap of Vertex Pharmaceuticals (VRTX)?

The market cap of Vertex Pharmaceuticals (VRTX) is approximately $136.0B.